AG

Arunlal Gopi

Active Director Director DIN 08102570
DIN 08102570 First appointment Apr 2018 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2018
Shareholding value •••• Premium profile

About Arunlal Gopi

Data last updated:

Arunlal Gopi is a Director at Midsun Pharmaceuticals Private Limited (since 2018). The company operates in Trading. Midsun Pharmaceuticals Private Limited reported revenue of ₹22.6 Lakh (FY 2025).

DIN 08102570
Primary Designation Director
Industry Trading
First Appointment 04 Apr 2018
Oldest Company Age 8 yrs
Largest company Midsun Pharmaceuticals Private Limited · ₹22.6 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director04 Apr 20182018₹22.6 Lakh (FY 2025)Active

Board colleagues of Arunlal Gopi

Directorship timeline

Open interactive timeline →
Midsun Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Arunlal Gopi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Arunlal Gopi

Arunlal Gopi currently holds 1 directorship: Midsun Pharmaceuticals Private Limited (Director, since 04 Apr 2018, revenue ₹22.6 Lakh (FY 2025)).

Arunlal Gopi was first appointed on 04 Apr 2018 as Director at Midsun Pharmaceuticals Private Limited.

The current boards of Arunlal Gopi's companies include Sumithra Sasidharan (Midsun Pharmaceuticals Private Limited), Yoosaf Faizal (Midsun Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available